NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
View PDF of blog article here
Operating like thieves under the cover of darkness, prominent academic-based "authorities" in medical specialties have debased academic standards and sold their reputations for cash-
This controversial, commercial experiment is being conducted without informed consent in trauma patients who require blood to survive. PolyHeme is being tested in patients in ambulances and at hospital emergency facilities where these trauma patients are denied life-saving real blood.
Sen. Grassley is peeling away psychiatry’s layers of deception about the efficacy and safety of its treatments: "I have come to understand that money from the pharmaceutical industry can shape the practices of nonprofit organizations that purport to be independent in their viewpoints and actions."
FDA Scientist Won’t Present New Pain Drug Data – FDA to Create Independent Drug Safety Board Tue, 15 Feb 2005 A culture of intimidation prevents FDA safety officers from disclosing important safety information about widely marketed drugs. Reuters reports: “Criticism of how the FDA monitors the after-market safety of drugs…
Given the serious charges against Dr. Kuklo–including fraud, forgery, and conducting an unapproved experiment on soldiers–the University of Washington’s failure to take action until a series of articles in The New York Times and pressure brought to bear by Sen. Charles Grassley, speaks volumes about a pervasive culture of arrogance in academia.
The primary promoters–inventors, one might say– of diagnosing children with "bipolar" disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.